US Emphysema Market Research Report By Type (centrilobular, panlobular), By Diagnosis (imaging test, lung function test, others, chest X-ray, CT scan), By Treatment (medications, therapy, surgery, smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, leukotriene modifiers, pulmonary rehabilitation, nutrition therapy, gene therapy, supplemental oxygen, lung volume reduction surgery, lung transplant, bullectomy) and By End-User (hospitals and clinics, surgical centers, others) - Forecast to 2035

US Emphysema Market Overview

As per MRFR analysis, the US Emphysema Market Size was estimated at 2.14 (USD Billion) in 2023. The US Emphysema Market Industry is expected to grow from 2.5 (USD Billion) in 2024 to 4.5 (USD Billion) by 2035. The US Emphysema Market CAGR (growth rate) is expected to be around 5.489% during the forecast period (2025 - 2035).

Key US Emphysema Market Trends Highlighted

The US Emphysema Market is characterized by several key trends driven by an increase in the prevalence of chronic obstructive pulmonary disease (COPD). Smoking remains a significant contributor to the disease, and public health campaigns focusing on smoking cessation are gaining traction. The rise of awareness regarding respiratory health and its prevention is leading patients to seek more effective treatments. Furthermore, the aging population in the US is a critical driver; as individuals age, the likelihood of developing emphysema increases, prompting a greater need for medical interventions and support.

Opportunities in the US market can be explored through advancements in treatment options, particularly inhalation therapies, which are becoming more personalized and effective. Biologics and new pharmacotherapies are emerging as areas of investment, with companies focusing on developing innovative solutions to address the unmet needs of emphysema patients. Enhanced diagnostic tools are also significant, enabling earlier detection and better disease management.

Recent trends show a shift towards telehealth services and digital health solutions, allowing patients to manage their condition from home, thus improving access to care. The integration of technology into health monitoring is becoming increasingly popular, empowering patients to take control over their health outcomes. Additionally, there is a growing emphasis on integrated care models that involve collaboration between respiratory specialists, primary care physicians, and nurses to provide holistic management of the disease, which fosters better healthcare delivery in the US. Overall, the dynamics affecting the US Emphysema Market signal a transformative period with opportunities for innovation and improved patient care.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Emphysema Market Drivers

Rising Prevalence of Chronic Respiratory Diseases

The rising prevalence of chronic respiratory diseases such as emphysema is a significant driver of the US Emphysema Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 15 million American adults have been diagnosed with chronic obstructive pulmonary disease (COPD), which encompasses emphysema. Furthermore, it has been projected that by 2030, the number of adults suffering from COPD may increase by 29 percent due to population aging and lifestyle factors, such as smoking and environmental pollution.

Given the aging population in the United States, where around 65 million citizens are projected to be aged 65 and older by 2035, the US Emphysema Market Industry can expect growth driven by an increasing patient base necessitating effective management options. Organizations such as the American Lung Association are actively advocating for awareness and research funding, which supports advancements in treatment modalities.

Advancements in Treatment Options

Significant advancements in treatment options for emphysema encourage growth in the US Emphysema Market Industry. Technologies such as minimally invasive surgical techniques and new pharmacological treatments have emerged, enhancing patient outcomes. The National Heart, Lung, and Blood Institute has emphasized that new biologic therapies have shown a 25% improvement in lung function in a subset of emphysema patients. Moreover, the innovation pipeline is robust, with numerous leading pharmaceutical companies such as Johnson and Johnson and AstraZeneca investing heavily in Research and Development.

These innovations are expected to result not only in improved quality of life for patients but also in a rising demand for products and therapies associated with the management of emphysema, thereby driving market growth.

Increasing Public and Private Healthcare Spending

Healthcare spending in the United States has been on the rise, creating a supportive framework for the US Emphysema Market Industry. According to the Centers for Medicare and Medicaid Services, total national health expenditures in the US have increased from $3.6 trillion in 2018 to $4.1 trillion in 2020, with expectations for further increases. This uptick in healthcare spending facilitates better access to treatments for chronic diseases like emphysema.

The increased reimbursement policies by Medicare and Medicaid for pulmonary rehabilitation services are particularly noteworthy, contributing to enhanced patient access and adherence to treatment protocols. Consequently, more patients are receiving necessary care, driving demand within the US Emphysema Market Industry.

Growing Awareness and Education Programs

There's a marked increase in public awareness and educational programs regarding emphysema facilitated by organizations like the American Lung Association. These campaigns aim to educate the public about the symptoms, risk factors, and importance of early diagnosis of emphysema. According to the National Institute of Health, studies indicate that individuals with a better understanding of lung health are 50% more likely to seek medical help when experiencing respiratory symptoms.

The emphasis on smoking cessation programs and air quality improvement initiatives has prompted individual actions that contribute to demand for treatment options. As more individuals become informed about their risk factors and available treatments, the US Emphysema Market Industry is likely to see a significant increase in patient populations and, consequently, market growth.

US Emphysema Market Segment Insights

Emphysema Market Type Insights

The US Emphysema Market showcases a diverse landscape, driven by key segment types, specifically centrilobular and panlobular emphysema, each contributing distinct characteristics and implications for patients and treatment strategies. Centrilobular emphysema primarily affects the central parts of the acini, typically linked to smoking or environmental toxins, making it a prevalent choice in cases resulting from chronic obstructive pulmonary disease (COPD). Given its association with significant respiratory complications, effective management solutions tailored to this segment are crucial, reflecting the underlying pathophysiology that demands targeted therapies and intervention strategies. 

On the other hand, panlobular emphysema is characterized by the uniform destruction of the entire acinus and is often associated with alpha-1 antitrypsin deficiency, a genetic disorder. The differentiation between centrilobular and panlobular types is significant, as it influences therapeutic approaches, patient management, and expected clinical outcomes. The increasing prevalence of lung diseases in the US, driven by both lifestyle choices and genetic factors, creates a burgeoning need for effective treatments tailored specifically to the types of emphysema that patients present. Research consistently indicates an upward trend in the demand for treatment solutions that address the unique pathophysiological features of these emphysema types. 

This segmentation not only directs pharmacologic advancement but also shapes the landscape of Research and Development initiatives targeting specific treatments for each type. Additionally, a growing awareness of these conditions among healthcare professionals enhances diagnostics and tailored care, further stimulating growth across the US Emphysema Market. As evidenced by ongoing public health campaigns and increased education around smoking cessation and lung health, the importance of understanding different emphysema types extends well beyond clinical implications, influencing societal health outcomes as well. 

Ultimately, the continued evolution of treatment protocols and support mechanisms for affected patients underscores the vitality of focusing on these distinct emphysema classifications, fostering both innovation and improved patient care in the US Emphysema Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Emphysema Market Diagnosis Insights

The Diagnosis segment of the US Emphysema Market plays a crucial role in effectively identifying and managing this chronic respiratory condition. It encompasses various methodologies, including imaging tests, lung function assessments, and other diagnostic approaches. Imaging tests, particularly chest X-rays and CT scans, are significant as they provide vital visual insights into lung health, helping physicians to detect structural changes indicative of emphysema. Lung function tests are essential for assessing the extent of airflow obstruction, directly guiding treatment decisions and ongoing management. 

The diversification within the Diagnosis segment enhances its efficacy, enabling healthcare providers to deliver tailored care for patients suffering from emphysema. With a rising prevalence of respiratory diseases in the US, driven by factors like smoking and pollution, the demand for advanced diagnostic tools continues to surge. Additionally, increasing awareness and effective healthcare policies contribute to market expansion by promoting early diagnosis and intervention, thus paving the way for improved patient outcomes and enhanced quality of life. The emphasis on accurate and timely diagnosis remains central to the US Emphysema Market, fostering continued advancements in technologies and methodologies to combat this debilitating disease.

Emphysema Market Treatment Insights

The Treatment segment of the US Emphysema Market plays a crucial role in managing this chronic respiratory condition, with a variety of approaches tailored to improve patient outcomes. Medications are a dominant force, especially bronchodilators and inhaled steroids, which help alleviate symptoms and improve lung function. Smoking cessation drugs are essential in aiding patients in quitting smoking, a significant risk factor for emphysema. Surgical interventions, such as lung volume reduction surgery and lung transplant, offer hope for severe cases, providing substantial quality-of-life improvements. The importance of therapy, including pulmonary rehabilitation and nutrition therapy, cannot be understated, as they equip patients with strategies to manage their condition effectively. 

Additionally, gene therapy and supplemental oxygen are gaining attention as innovative approaches that may redefine treatment protocols. Bullectomy is also recognized for its role in addressing large bullae that can impede lung function. With the growing focus on personalized care and advancements in treatment options, the market is witnessing a shift in patient management strategies that prioritize both efficacy and quality of life. The increasing prevalence of emphysema in the US, alongside an aging population, further propels the demand for effective treatment solutions, indicating a robust growth trajectory for this segment.

Emphysema Market End-User Insights

The End-User segment of the US Emphysema Market presents diverse opportunities across various healthcare settings, notably hospitals, clinics, and surgical centers. Hospitals and clinics represent a critical part of the US healthcare infrastructure, providing essential services for the diagnosis and treatment of emphysema, likely sustaining a substantial portion of the market. Surgical centers support a growing emphasis on outpatient procedures and minimally invasive techniques, driving demand for innovative treatment options. Moreover, changes in care models and increased healthcare spending in the United States further drive growth within these End-User categories. 

As the population ages and incidences of respiratory diseases rise, there is a reinforced need for advanced therapeutic solutions, thereby ensuring that hospitals and clinics remain prominent in service delivery. The ongoing expansion and modernization of these facilities are vital to effectively accommodate the growing patient base while ensuring access to state-of-the-art medical care. The overall dynamics of the US Emphysema Market segmentation underscore a critical shift toward integrated healthcare delivery systems, positioning these End-User sectors as key players in addressing the challenges associated with this chronic respiratory condition.

US Emphysema Market Key Players and Competitive Insights

The US Emphysema Market has seen significant growth and transformation in recent years, driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD), including emphysema, among the population. Several pharmaceutical companies are competing to develop advanced therapies aimed at alleviating symptoms and improving the quality of life for patients. Innovation in drug formulation, delivery mechanisms, and ongoing clinical research plays a central role in this competitive landscape. Market players are also focused on partnerships and collaborations, which can lead to more effective treatments and expand their market presence. The regulatory environment, patient access to therapies, and the push towards personalized medicine further shape the dynamics within this market, making it an area of keen interest for investors and healthcare providers alike.

Vertex Pharmaceuticals has established a notable presence in the US Emphysema Market with a strong emphasis on research and development. The company's focus on innovative treatment options positions it as a vital player in addressing the unmet needs of patients suffering from emphysema. Vertex Pharmaceuticals is recognized for its commitment to advancing therapies through robust clinical trials and collaborations with research institutions, which strengthen its market position. The company's agile approach to market demands, combined with its efficient supply chain and responsive customer support, has allowed it to carve a niche in this specialized market. Furthermore, the strategic focus on patient engagement and educational initiatives enhances its reputation among both healthcare professionals and patients, further solidifying its competitive edge.

AstraZeneca plays a significant role in the US Emphysema Market, with a portfolio that includes several key products aimed at managing COPD and its associated symptoms. The company’s flagship offerings are among the leading therapies available, reflecting its commitment to addressing both the clinical and personal needs of patients. AstraZeneca leverages its extensive research capabilities and strong pipeline to continuously innovate and bring new therapies to market, reinforcing its position as a leader in pulmonary medicine. 

The company has also been active in mergers and acquisitions to enhance its therapeutic offerings and expand its market share. These strategic initiatives have enabled AstraZeneca to maintain a competitive advantage and ensure that it meets the evolving needs of the healthcare landscape in the US. By prioritizing patient-centric approaches and emphasizing real-world evidence in its research, AstraZeneca not only addresses current market demands but also contributes to the broader understanding of emphysema treatment and management.

Key Companies in the US Emphysema Market Include

• Vertex Pharmaceuticals


• AstraZeneca


• Novartis


• GlaxoSmithKline


• Eli Lilly


• BristolMyers Squibb


• Gilead Sciences


• United Therapeutics


• Boehringer Ingelheim


• Pfizer


• Amgen


• Roche


• Mylan


• Teva Pharmaceuticals


• Sun Pharmaceutical

US Emphysema Market Industry Developments

The US Emphysema Market has witnessed significant developments in recent months, particularly driven by advancements in treatment options. Vertex Pharmaceuticals has made strides in Research and Development for innovative therapies aimed at treating emphysema. AstraZeneca continues to expand its pipeline with new inhaled therapies, focusing on improving patient outcomes. Novartis and GlaxoSmithKline are engaged in ongoing studies targeting the inflammation pathways associated with emphysema. 

Additionally, Eli Lilly and Bristol Myers Squibb are collaborating on a clinical study to evaluate the efficacy of a combination therapy that could enhance breathing function in patients. There have been reports of market growth, with companies like Gilead Sciences and United Therapeutics experiencing a valuation increase due to their novel approaches to respiratory diseases. In terms of mergers and acquisitions, in July 2023, Boehringer Ingelheim acquired a small biotech firm specializing in lung diseases, enhancing their portfolio in the emphysema space. Pfizer and Amgen have also announced partnerships aimed at accelerating the development of therapies that target emphysema-related complications. Market dynamics show an increasing investment in treatments, reflecting an ongoing commitment to addressing this chronic condition.

US Emphysema Market Segmentation Insights

Emphysema Market Type Outlook

• centrilobular


• panlobular

Emphysema Market Diagnosis Outlook

• imaging test


• lung function test


• others




• chest X-ray


• CT scan

Emphysema Market Treatment Outlook

• medications




• smoking cessation drugs


• bronchodilators


• inhaled steroids


• antibiotics


• leukotriene modifiers




• therapy




• pulmonary rehabilitation


• nutrition therapy




• surgery




• gene therapy


• supplemental oxygen


• lung volume reduction surgery


• lung transplant


• bullectomy

Emphysema Market End-User Outlook

• hospitals and clinics


• surgical centers


• others

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	2.14(USD Billion)
MARKET SIZE 2024	2.5(USD Billion)
MARKET SIZE 2035	4.5(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.489% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Vertex Pharmaceuticals, AstraZeneca, Novartis, GlaxoSmithKline, Eli Lilly, BristolMyers Squibb, Gilead Sciences, United Therapeutics, Boehringer Ingelheim, Pfizer, Amgen, Roche, Mylan, Teva Pharmaceuticals, Sun Pharmaceutical
SEGMENTS COVERED	Type, Diagnosis, Treatment, End-User
KEY MARKET OPPORTUNITIES	Telehealth respiratory solutions, Innovative drug delivery systems, Home-based oxygen therapies, Enhanced pulmonary rehabilitation programs, Advanced diagnostic imaging tools
KEY MARKET DYNAMICS	increasing prevalence of smoking, rising aging population, advancements in treatment options, growing awareness and diagnosis, high healthcare costs
COUNTRIES COVERED	US